
    
      This study is a randomized, unblinded, multi-center trial with parallel group design, with
      subjects randomized to either control (optimized medical therapy for chronic heart failure)
      or active treatment (optimized medical therapy plus use of MV-targeted ASV) in a 1:1 ratio.
    
  